France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases. http://www.topix.com/business/pharmaceuticals/2018/01/frances-sanofi-buys-us-hemophilia-specialist-bioverativ?fromrss=1
The conversations may be about Amazon taking a role in drug purchasing, competing against distributors like McKesson, AmerisourceBergen, and Cardinal Health. https://www.biospace.com/article/around-the-web/amazon-in-exploratory-talks-with-mylan-novartis-about-pharma-entry-/
The regulator hopes to improve how it reviews digital medical devices, aiming to streamline the path to market for new health tools. http://www.healthcaredive.com/news/apple-fitbit-among-companies-selected-for-fda-digital-health-precertificat/505867/
The positive results in the clinical trial help validate Alnylam’s $7 billion market valuation and pave the way for more drugs based on RNAi technology. https://www.statnews.com/2017/09/20/alnylam-drug-success/
Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined. http://www.biopharmadive.com/news/bristol-roche-tap-halozyme-for-tech-platform/504958/
FRANKFURT (Reuters) – AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.
THOUSAND OAKS, Calif. and LOUISVILLE, Ky., Aug. 17, 2017 /PRNewswire/ — Two of the nation’s leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to identify opportunities to improve health… http://www.prnewswire.com/news-releases/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency-300506215.html
What does Pfizer animal health spinoff Zoetis share with its former parent, aside from its lineage? They’re both under pressure from investors to drive growth through acquisitions. Zoetis met second-quarter expectations and brightened its forecast for the rest of the year, and now it’s looking to M&A to drive further growth. http://www.fiercepharma.com/financials/pfizer-spinoff-zoetis-ups-2017-guidance-eyes-m-a-for-future-growth